Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 15,582

Document Document Title
WO/2020/085373A1
The present invention provides a novel compound which has activating activity selective for ERβ. A compound represented by formula (1) or a salt thereof. (In the formula, R1 represents a cycloalkyl group having 3-8 carbon atoms, an alke...  
WO/2020/072324A1
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for ...  
WO/2020/072456A1
Disclosed is a pharmaceutical composition comprising a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of tre...  
WO/2020/067398A1
The purpose of the present invention is to provide: a novel compound that inhibits cell invasion of filovirus; a medicinal composition that comprises the compound; an anti-filovirus agent or an inhibitor for cell invasion of filovirus; a...  
WO/2020/061293A1
The present disclosure relates to compounds useful as shielding agents for PSMA therapies. The present disclosure relates to methods of treating PSMA expressing cancers with one or more radiotherapeutics agents in combination with one or...  
WO/2020/059841A1
The purpose of the invention is to provide a compound which has the effect of suppressing abnormal prion production and is useful as a therapeutic agent for prion diseases. Provided are a compound represented by formula (I) (the symbols ...  
WO/2020/054226A1
A thermal base generator is represented by formula (N1). This photosensitive resin composition contains the thermal base generator and a precursor of a heterocycle-containing polymer. In formula (N1), RN1 and RN2 each independently repre...  
WO/2020/050160A1
A hydrogenation catalyst for amide compounds which comprises hydroxyapatite and, fixed thereto, platinum and vanadium, characterized in that 15-80% of the surface of the platinum is covered with vanadium. With the catalyst, it is possibl...  
WO/2020/051207A2
The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presenc...  
WO/2020/046515A1
The present disclosure provides a quaternary ammonium hydroxide solution comprising a reaction product of a polyamine and an organic oxirane. The quaternary ammonium hydroxide solution may be used in various applications, such as in remo...  
WO/2020/042876A1
The present application relates to a synthesis method for cariprazine, comprising performing an acylation reaction between a compound represented by formula (I) and dimethylcarbamoyl chloride in a reaction solvent in the presence of an a...  
WO/2020/039092A2
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/039094A1
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/039088A2
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/039631A1
Disclosed is a compound represented by formula (1): Q-CHR2 (1) (in the formula, Q represents a nitrogen-containing aliphatic group that includes two or more tertiary nitrogen atoms, and does not include oxygen, and R represents an alipha...  
WO/2020/035464A1
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 and R3 are each independently hydrogen or an optionally substituted hydrocarbyl group, or R1 and R3 together with the nitrogen atom to which...  
WO/2020/036661A2
The disclosure relates to a method for forming aryl carbon-nitrogen bonds and to photoreactors useful in these and other light-driven reactions. The method comprises contacting an aryl halide with an amine in the presence of a Ni salt ca...  
WO/2020/035825A1
The present invention disclosed novel phenylamidine compounds of formula (I), wherein, Cy, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and m have the same meanings as defined in the description.The present invention further discloses a proce...  
WO/2020/035031A1
Provided are fused ring compounds of Formula (I), Formula (II), or Formula (III), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods treatment by ...  
WO/2020/031986A1
The present invention addresses the problem of providing: a compound which exhibits high solubility in a solvent, while having a satisfactory sensitivity (base generation capacity); a polymerizable composition which contains this compoun...  
WO/2020/027304A1
Provided are carotenoid derivatives having exceptional hydrophilicity and oral absorptivity. A carotenoid-related compound represented by the formula (in the formula, X represents a carbonyl group or a methylene group, and Z1 and Z2 are ...  
WO/2020/027150A1
A compound represented by general formula (I) (wherein each symbol is as defined in the description) or a salt thereof has a potent neural protecting and/or repairing effect and, therefore, is usable as a therapeutic agent for neurologic...  
WO/2020/023793A1
Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.  
WO/2020/021021A1
The present invention relates to ortho substituted phenoxypropylamino and benzyloxypropylamino derivatives having pharmacological activity towards the α2δ subunit of the voltage-gated calcium channel, in particular to ortho substituted...  
WO/2020/023794A1
Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.  
WO/2020/013108A1
To provide a drug for enabling the treatment or prevention of diseases which are caused by mitochondrial dysfunction and called mitochondrial diseases. In particular, to search for a function effect on mitochondrial diseases, said functi...  
WO/2020/011147A1
Provided herein are compounds as RORγ antagonist having Formula (I). The compounds or pharmaceutical composition thereof can be used for regulating Retinoid-related orphan receptor gamma t (RORγt). Also provided herein are methods of p...  
WO/2020/007834A1
The present inventionrefers to a crystalline salt comprising5-methyl-(6S)- tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine wherein the molar ratio of -methyl-(6S)-tetrahydrofolic acid to 4-(2-hydroxyethyl)-morpholine is from 1:0.3...  
WO/2020/009166A1
Disclosed is a polyoxometalate compound having a metal-substituted polyoxometalate. The metal-substituted polyoxometalate comprises a polyoxometalate having a defect site, a substituting metal atom introduced into the defect site, and an...  
WO/2020/004601A1
Provided are: an oxime ester compound useful as a photopolymerization initiator used in a polymerizable composition; and a photopolymerization initiator containing the oxime ester compound. This compound has a group represented by genera...  
WO/2020/006353A1
A compound represented by the structure of formula(I): The compound is useful as a ligand for ruthenium to form an organometallic complex. The complex may be immobilized on an oxidic support to form an active, heterogeneous catalyst for ...  
WO/2020/002238A1
The present invention provides compounds of formula (I) for use in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).  
WO/2020/001298A1
Provided in the present invention are a 4-(p-trifluoromethylbenzyl)-3-floro-1,2,4 triphenylamine derivative, a pharmaceutical composition of same, and uses thereof. The chemical formula of the derivative is as represented by formula I, w...  
WO/2020/006341A1
The present invention relates to (S)-3-(2-(4-(benzyl)-3-oxopiperazin-l- yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating e.g. cardiovascular, kidney, li...  
WO/2019/242889A1
The present invention relates to a novel process for the preparation of Vortioxetine and a key intermediate thereof by employing a novel one-pot organo-pseudocatalytic C-H activation approach via hypervalent iodine chemistry.  
WO/2019/238960A1
The present invention relates to a new type of low-dimensional hybrid post-perovskites for high efficiency white light emission. More precisely, the invention relates to a one dimensional post-perovskite of formula AaMmXx.yH2O wherein A ...  
WO/2019/241131A1
Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treati...  
WO/2019/234728A1
The present invention provides THCA- and CBDA-derivatives, and pharmaceutical compositions thereof. These compounds are non-classical cannabinoids that are either agonists or antagonists of the peripheral CB1 and/or CB2 receptors, and ar...  
WO/2019/236710A1
The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.  
WO/2019/235635A1
The present invention addresses the problem of providing: a compound or a salt thereof, which constitutes lipid particles that enable the achievement of high nucleic acid encapsulation rate and excellent nucleic acid delivery; and lipid ...  
WO/2019/232095A1
Disclosed are cationic lipids comprising a vitamin substructure and an ionizable nitrogen- containing group. Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of l...  
WO/2019/226490A1
Provided is a compound of Formula (I), wherein the variable groups are defined herein.  
WO/2019/218864A1
Disclosed is a method of preparing an organic amine ester derivative drug of 2-(α-hydroxypentyl)benzoic acid and a use thereof. In particular, the present disclosure relates to a compound represented by formula I or a pharmaceutically a...  
WO/2019/222105A1
A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I: R20 –(Z)b–(Y)c–(R21)a–(X)d–R22–R23 wherein R20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted...  
WO/2019/214084A1
Provided is a method for biocatalytic synthesis of Sitagliptin and intermediates thereof, in particular, provided are compounds of Formula (I) and Formula (II), or pharmaceutically acceptable salts thereof, a polypeptide capable of catal...  
WO/2019/216355A1
The present invention relates to: a method for converting a hydroxyl group of an alcohol; and a catalyst which makes the method possible. A method for converting a hydroxyl group of an alcohol according to the present invention is charac...  
WO/2019/216810A1
Compounds of the formulae wherein the bond α is a single bond, a trans double bond (E), or a triple bond; X and Y are -CH2- or on of X and Y is O and the other is CH2; R1 is phenyl unsubstituted or substituted with one, two, or three su...  
WO/2019/217977A1
Disclosed herein are compounds represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables in Structural Formula I are described herein. The compounds can be used to modulate (e.g, inhib...  
WO/2019/213160A1
This disclosure provides compounds with Bcl inhibitory activity. Acyl phosphonamidate compounds may include a P-phenyl phosphonamidate moiety which is N-acylated with an aroyl or heteroaroyl group. One of the heteroatoms attached to phos...  
WO/2019/199864A1
The present disclosure relates to tri-substituted aryl and heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for modulating autophagy or preventing, reversing, slowing or in...  

Matches 451 - 500 out of 15,582